Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
Science Translational Medicine | January 17, 2019 | Volume: 11 | Issue: 475 | Pages: No page available
10.1126/scitranslmed.aau3441
| PMID 30651321
A hepatoselective glucokinase activator reduced hyperglycemia without hypoglycemia or adverse effects on lipids, liver enzymes, or blood pressure.